Beijing Aosaikang Pharmaceutical (002755.SZ) announced the performance forecast for the first half of 2024, and based on preliminary calculations by the financial department, it is expected to achieve a net profit attributable to shareholders of the listed company of RMB 66 million to RMB 85 million in the first half of 2024, compared to a loss of RMB 158.4523 million in the same period last year. After deducting non-recurring gains and losses, the net profit is expected to be RMB 45 million to RMB 58 million, compared to a loss of RMB 183.5443 million in the same period last year. The basic earnings per share are expected to be between RMB 0.07/share and RMB 0.09/share.
Explanation for changes in performance: 1. Increase in revenue: The sales growth of the company's anti-infective and chronic disease products is relatively fast, and the company's revenue has achieved year-on-year growth, further improving profitability. 2. Decrease in research and development expenses: The company continues to conduct analysis, evaluation, and optimization of research and development projects, focusing on promoting the research and development of key advantaged varieties. Some of the company's new drugs have completed the key clinical research and development stage with large investment. Therefore, research and development expenses decreased year-on-year without the need for large-scale research and development investments for related projects during the reporting period. 3. Significant effects in controlling costs: The company continuously strengthens cost management, optimizes various expense expenditures, reduces production costs, sales expenses, and management expenses, and effectively controls costs.